In: European Journal of Cardio-Thoracic Surgery, 2009, vol. 35, no. 5, p. 749-750
|
In: European Journal of Cardio-Thoracic Surgery, 2012, vol. 41, no. 4, p. e25-e31
|
In: European Heart Journal, 2009, vol. 30, no. 23, p. 2921-2929
|
In: European Heart Journal, 2011, vol. 32, no. 7, p. 799-809
|
In: European Heart Journal, 2004, vol. 25, no. 16, p. 1438-1446
|
In: European Heart Journal, 2012, vol. 33, no. 8, p. 988-997
|
In: European Heart Journal, 2004, vol. 25, no. 1, p. 69-80
|
In: European Heart Journal, 2007, vol. 28, no. 17, p. 2110-2117
|
In: European Journal of Cardio-Thoracic Surgery, 2011, vol. 40, no. 6, p. 1550-1550
|
In: Trials, 2014, vol. 15, no. 1, p. 9
Background: Second-generation everolimus-eluting stents (EES) and third generation biolimus-eluting stents (BES) have been shown to be superior to first-generation paclitaxel-eluting stents (PES) and second-generation sirolimus-eluting stents (SES). However, neointimal proliferation and very late stent thrombosis is still an unresolved issue of drug-eluting stent (DES) implantation overall. The...
|